ClinicalTrials.gg
Active, not recruitingNCT06729853Updated Dec 11, 2024

PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function

A Phase 1/2 interventional study of SAP-001 in Gout and Hyperuricemia, sponsored by Shanton Pharma Pte. Ltd.. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by Shanton Pharma Pte. Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as active, not recruiting.
  • Registered 7 months after the study started (first participant enrolled Apr 2024, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Gout with a site in United States — 12 open to participants now, 16 under way, 3 of them phase 3. Gout · United States.

Planned enrollment
105th of 149
32 · median 74
Started
2024
with 7 others
Phase 1/2
2 of 164
none open now
Primary completion
2025-01
later than 1 of 15 live
Registered
152nd of 164
by date

Among the 164 studies in Gout with a site in United States, this one is the 105th largest by planned enrollment of the 149 interventional ones that give a count, is one of 8 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 1 of the 15 other live ones, and was the 152nd registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

12 of the 164 studies in Gout with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Gout with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open-label, non-randomized, parallel-group, single-dose, 2-part, adaptive study in which up to approximately 32 adult subjects will be enrolled in one of 4 groups (8 subjects per group) with varying degrees of renal function.

03

Conditions studied

  • Gout
  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects:

  1. Provision of signed and dated form (ICF)
  2. Subject is, as stated and in the opinion of the Investigator, willing and able to comply with the study drug regimen and all other protocol and study procedures and requirements, and is available for the duration of the study
  3. Adult male or female
  4. Subject is willing to comply with the requirements as defined in APPENDIX 6
  5. Aged at least 18 years but not older than 80 years
  6. ≥ 18.5 kg/m2 and \< 42.0 kg/m2 at the time of Screening.
  7. Light-, non- or ex-smoker (A light smoker is defined as someone using 10.0 nicotine units [1 unit = 1 cigarette] or less per day for at least 90 days prior to study drug administration. An ex-smoker is defined as someone who completely stopped using nicotine products for at least 180 days prior to study drug administration)
  8. Having suitable venous access for blood sampling

    Subjects with Normal Renal Function (Group 4):

  9. Have no diseases captured in the medical history or evidence of clinically significant findings on the laboratory tests, physical examination (including vital signs) and/or , as determined by an Investigator
  10. Normal renal function with estimated (eGFR) ≥ 90 mL/minute at Screening
  11. Must match to the pooled mean age (± 10 years), BMI (within 20%) and sex (ratio should be similar) of mild, moderate (if applicable), and severe (if applicable) renal impaired subjects

    Subjects with mild, moderate, or severe renal impairment (Groups 1, 2 and 3, respectively):

  12. Considered clinically stable in the opinion of an Investigator
  13. Presence of mild renal impairment (eGFR ≥ 60 and \< 90 mL/min), moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min) or severe renal impairment (eGFR≥ 15 and \< 30 mL/min) at Screening. Renal impairment should be stable for at least 1 month prior to Screening (change in eGFR should not be more than 25%).

Note: The Investigator can order a repeat of eGFR if it is determined that the initial value is inconsistent with the historical values for a particular subject

Exclusion criteria

Exclusion Criteria:

All subjects:

  1. Female who is lactating
  2. Female who is pregnant according to the pregnancy test at Screening or prior to study drug administration
  3. History of significant to SAP-001 or any related products (including of the formulation) as well as severe hypersensitivity reactions (like angioedema) to any drugs
  4. Positive screening results to Ag/Ab Combo and surface antigen (HBsAg)
  5. Positive reflex test for antibody (positive Hepatitis C antibody is allowed if HCV RNA is not detected)
  6. Presence or history of any disorder that could interfere with completion of the study based on the opinion of an Investigator
  7. Intake of SAP-001 or any Product (IP) in the 28 days (or 5 times the half-life of the drug, whichever is longer) prior to study drug administration
  8. Have urinary incontinence without catheterization
  9. Reception of blood products within 3 months prior to study drug administration
  10. Donation of 50 mL or more of blood in the 28 days prior to Screening
  11. Donation of 500 mL or more of blood within 56 days prior to Screening.
  12. Donation of plasma within 2 weeks prior to Screening or within 6 weeks prior to Screening
  13. Inclusion in a previous group for this clinical study

    Subjects with Normal Renal Function (Group 4):

  14. Presence of significant gastrointestinal, liver, or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs or known to potentiate or predispose to undesired effects
  15. History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability
  16. Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
  17. Presence of out-of-range cardiac interval (eg, > 440 msec) based on the mean of the triplicate values at Screening or other ECG abnormalities, unless deemed non-significant by an Investigator
  18. Positive test result for alcohol and/or drugs of abuse at Screening or prior to study drug administration
  19. Seated blood pressure below 90/60 mmHg at Screening and prior to dosing
  20. Seated blood pressure higher than 140/90 mmHg at Screening and prior to dosing
  21. Seated pulse rate less than 40 beats per minutes (bpm) or more than 100 bpm at Screening and prior to dosing
  22. Any clinically significant illness in the 28 days prior to study drug administration
  23. Use of any prescription drugs (with the exception of hormonal or hormone replacement therapy) in the 28 days prior to study drug administration that, in the opinion of an Investigator, would put into question the status of the participant as healthy
  24. Use of St. John's wort in the 28 days prior to study drug administration
  25. Use of over-the-counter drugs and natural health products (eg, herbal remedies) in the 14 days (or 5 times the half-life of the drug, whichever is longer) prior to study drug administration
  26. Use of any enzyme-modifying drugs, or drugs with effects on membrane transporters, including any strong cytochrome P450 3A4 and P-glycoprotein inducers and inhibitors in the previous 28 days prior to study drug administration

    Subjects with Renal Impairment (Groups 1, 2 and 3):

  27. History of renal transplant
  28. Seated blood pressure below 100/50 mmHg at Screening and prior to dosing
  29. Seated blood pressure higher than 180/100 mmHg at Screening and prior to dosing
  30. Seated pulse rate less than 50 bpm or more than 110 bpm at Screening and prior to dosing
  31. History or presence, in the opinion of an Investigator, of significant clinically unstable respiratory, cardiovascular, pulmonary, hepatic, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
  32. Presence of poorly controlled Type 1 or Type 2 diabetes as defined by > 10%
  33. Presence of clinically significant physical examination, laboratory test, or ECG finding that, in the opinion of an Investigator and/or Sponsor, may interfere with any aspect of study conduct or interpretation of results
  34. Subjects requiring treatment for renal impairment or other chronic disease (eg, well-controlled diabetes, hypertension) must be on a stable treatment plan (medicines, doses, and regimens) for at least 14 days (except insulin) prior to study drug administration and during the entire study. Small adjustments in the dosages of some concomitant medications may be permitted during the study and will be discussed on a case-by-case basis. In all cases, the subjects' treatment history must be reviewed and their enrollment must be agreed to by both an Investigator and the Sponsor's Medical Monitor
  35. Positive screening of alcohol and/or drugs of abuse at Screening or prior to study drug administration unless results can be explained by a prescription medication
  36. Concurrent use of medications known to affect the elimination of serum creatinine (eg, trimethoprim/sulfamethoxazole [Bactrim®] or cimetidine [Tagamet®]) and competitors of renal tubular secretion (eg, probenecid) within 30 days prior to study drug administration or anticipated need for these therapies through to the last PK sample of the study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Mild renal impairment

    Subjects with mild renal impairment

    Drug: SAP-001

  • Experimental
    Moderate renal impairment

    Subjects with moderate renal impairment

    Drug: SAP-001

  • Experimental
    Severe renal impairment

    Subjects with severe renal impairment(Optional)

    Drug: SAP-001

  • Experimental
    Healthy match

    Matched healthy subjects with normal renal function

    Drug: SAP-001

Interventions

  • a single oral dose of SAP-001

06

What researchers measure

Primary outcomes

  1. maximum observed concentration (Cmax)

    The primary PK endpoints

    Time frame: day 8

  2. AUC from time 0 to time of last quantifiable sample (AUC0-T)

    The primary PK endpoints

    Time frame: day 8

  3. apparent clearance (CL/F)

    The primary PK endpoints

    Time frame: day 8

Secondary outcomes

  1. time to maximum concentration (Tmax)

    Plasma PK parameters

    Time frame: day 8

  2. AUC from time 0 extrapolated to infinity (AUC0-∞)

    Plasma PK parameters

    Time frame: day 8

  3. terminal elimination half-life (Thalf)

    Plasma PK parameters

    Time frame: day 8

  4. volume of distribution (Vz/F)

    Plasma PK parameters

    Time frame: day 8

  5. Ae(0-T) (amount excreted)

    Urine PK parameters:

    Time frame: day 8

  6. Fraction of dose excreted in urine (fe)

    Urine PK parameters:

    Time frame: day 8

  7. CLr (renal clearance)

    Urine PK parameters:

    Time frame: day 8

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Jan 2025, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2024
First posted
Dec 11, 2024
StartActual
Apr 24, 2024
Primary completionEst.
Jan 17, 2025
CompletionEst.
Apr 28, 2025
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06729853
Lead sponsor
Shanton Pharma Pte. Ltd.
Responsible party
Sponsor
First posted
Dec 11, 2024
Start date
Apr 24, 2024
Primary completion
Jan 17, 2025 (estimated)
Completion
Apr 28, 2025 (estimated)
Last update
Dec 11, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SAP-001

Start the discussion